GlassScriptPhysician profile
Lee Ann Turner
NPI 1366606238
$2,606.77
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $824 · 2022: $1,035 · 2023: $728 · 2024: $19.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.45 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $388.81 | 2021-2023 | Kyprolis, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $187.98 | 2021-2023 | Ninlaro |
| Astrazeneca Pharmaceuticals LP | $174.10 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $166.91 | 2022-2023 | Imbruvica |
| Lilly USA, LLC | $160.76 | 2021-2023 | Verzenio |
| Merck Sharp & Dohme LLC | $159.94 | 2021-2023 | Keytruda |
| Pfizer INC. | $139.51 | 2021-2023 | |
| Astellas Pharma US INC | $119.24 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $111.56 | 2022-2023 | Opdivo |
| Myovant Sciences INC. | $109.00 | 2021-2022 | |
| Eisai INC. | $85.22 | 2021-2022 | |
| Genzyme Corporation | $76.65 | 2022-2023 | |
| Emd Serono, INC. | $66.03 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $52.06 | 2023 | Precisetumor |
| Taiho Oncology, INC. | $51.11 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $48.17 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $47.11 | 2022-2023 | Libtayo |
| Puma Biotechnology, INC. | $45.22 | 2021-2022 | |
| Seagen INC. | $43.94 | 2021-2022 | |
| Janssen Biotech, INC. | $42.31 | 2022-2023 | Rybrevant, Darzalex |
| Daiichi Sankyo INC. | $41.53 | 2021-2022 | |
| Blueprint Medicines Corporation | $33.88 | 2023 | Ayvakit |
| Pharmaessentia USA Corporation | $33.08 | 2022 | |
| Sobi, INC | $32.66 | 2022 | |
| Beigene USA, INC. | $32.39 | 2022-2023 | Brukinsa |
| Acrotech Biopharma INC. | $25.73 | 2022 | |
| Glaxosmithkline, LLC. | $21.38 | 2021 | |
| Incyte Corporation | $20.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.88 | 2021 | |
| Abbvie INC. | $19.72 | 2024 | |
| Heron Therapeutics, INC. | $18.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2021 | |
| Celgene Corporation | $15.33 | 2023 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Ann Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.